Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$54.2 - $69.69 $157,180 - $202,101
-2,900 Reduced 17.06%
14,100 $974,000
Q4 2023

Feb 14, 2024

BUY
$48.72 - $65.43 $448,224 - $601,956
9,200 Added 117.95%
17,000 $937,000
Q3 2023

Nov 14, 2023

SELL
$50.28 - $64.61 $30,168 - $38,766
-600 Reduced 7.14%
7,800 $452,000
Q2 2023

Aug 14, 2023

BUY
$37.29 - $53.83 $123,057 - $177,639
3,300 Added 64.71%
8,400 $452,000
Q1 2023

May 15, 2023

SELL
$37.61 - $45.72 $60,176 - $73,152
-1,600 Reduced 23.88%
5,100 $202,000
Q4 2022

Feb 14, 2023

SELL
$31.9 - $41.95 $382,800 - $503,400
-12,000 Reduced 64.17%
6,700 $269,000
Q3 2022

Nov 14, 2022

SELL
$29.83 - $38.01 $1.03 Million - $1.31 Million
-34,500 Reduced 64.85%
18,700 $601,000
Q2 2022

Aug 15, 2022

SELL
$23.09 - $33.46 $745,807 - $1.08 Million
-32,300 Reduced 37.78%
53,200 $1.58 Million
Q1 2022

May 16, 2022

SELL
$26.91 - $47.15 $34,983 - $61,295
-1,300 Reduced 1.5%
85,500 $2.4 Million
Q4 2021

Feb 14, 2022

BUY
$32.97 - $56.85 $1.61 Million - $2.77 Million
48,800 Added 128.42%
86,800 $4 Million
Q3 2021

Nov 15, 2021

SELL
$26.48 - $35.99 $254,208 - $345,504
-9,600 Reduced 20.17%
38,000 $1.25 Million
Q2 2021

Aug 16, 2021

SELL
$31.86 - $38.6 $248,508 - $301,080
-7,800 Reduced 14.08%
47,600 $1.67 Million
Q1 2021

May 17, 2021

SELL
$28.4 - $36.14 $45,440 - $57,824
-1,600 Reduced 2.81%
55,400 $2 Million
Q4 2020

Feb 16, 2021

BUY
$23.69 - $31.47 $35,535 - $47,205
1,500 Added 2.7%
57,000 $1.66 Million
Q3 2020

Nov 16, 2020

BUY
$26.38 - $33.1 $379,872 - $476,640
14,400 Added 35.04%
55,500 $1.57 Million
Q2 2020

Aug 14, 2020

BUY
$29.93 - $50.1 $1.23 Million - $2.06 Million
41,100 New
41,100 $1.33 Million

Others Institutions Holding ANIP

About ANI PHARMACEUTICALS INC


  • Ticker ANIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 17,426,000
  • Market Cap $973M
  • Description
  • ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose produc...
More about ANIP
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.